These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 15277727

  • 1. [Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction].
    Tsutamoto T.
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):90-100. PubMed ID: 15277727
    [Abstract] [Full Text] [Related]

  • 2. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
    Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M.
    Circulation; 2003 May 27; 107(20):2559-65. PubMed ID: 12732605
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA.
    Circ Heart Fail; 2010 May 27; 3(3):347-53. PubMed ID: 20299607
    [Abstract] [Full Text] [Related]

  • 4. [Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction].
    Hayashi M.
    J Cardiol; 2004 Feb 27; 43(2):88-91. PubMed ID: 15046031
    [Abstract] [Full Text] [Related]

  • 5. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
    Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ.
    Am Heart J; 2009 Jun 27; 157(6):1088-96. PubMed ID: 19464421
    [Abstract] [Full Text] [Related]

  • 6. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V, Torre-Amione G, Koerner MM.
    Curr Opin Cardiol; 2004 Jul 27; 19(4):301-8. PubMed ID: 15218387
    [Abstract] [Full Text] [Related]

  • 7. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
    Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K, Ichikawa S, Matsumoto N, Sato Y, Kurabayashi M.
    Int J Cardiol; 2013 Jul 15; 167(1):244-9. PubMed ID: 22245478
    [Abstract] [Full Text] [Related]

  • 8. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
    Fügedi K.
    Orv Hetil; 2005 Apr 03; 146(14):645-8. PubMed ID: 15889538
    [Abstract] [Full Text] [Related]

  • 9. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B.
    J Card Fail; 2002 Dec 03; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [Abstract] [Full Text] [Related]

  • 10. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.
    Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Matsui T, Fujii M, Matsumoto T, Yamamoto T, Horie H, Ohnishi M, Kinoshita M.
    J Am Coll Cardiol; 2001 Nov 01; 38(5):1375-82. PubMed ID: 11691511
    [Abstract] [Full Text] [Related]

  • 11. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J.
    J Am Coll Cardiol; 2003 Nov 05; 42(9):1666-73. PubMed ID: 14607457
    [Abstract] [Full Text] [Related]

  • 12. Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?
    Vatankulu MA, Bacaksiz A, Sonmez O, Alihanoglu Y, Koc F, Demir K, Gul EE, Turfan M, Tasal A, Kayrak M, Yazici M, Ozdemir K.
    Cardiovasc Ther; 2013 Aug 05; 31(4):224-9. PubMed ID: 22963506
    [Abstract] [Full Text] [Related]

  • 13. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D, Galuppo P, Schmidt I, Ertl G, Bauersachs J.
    Cardiovasc Res; 2005 Jul 01; 67(1):97-105. PubMed ID: 15949473
    [Abstract] [Full Text] [Related]

  • 14. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
    Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Horie H, Sugimoto Y, Kinoshita M.
    J Am Coll Cardiol; 2000 Sep 01; 36(3):838-44. PubMed ID: 10987608
    [Abstract] [Full Text] [Related]

  • 15. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
    Orea-Tejeda A, Colín-Ramírez E, Castillo-Martínez L, Asensio-Lafuente E, Corzo-León D, González-Toledo R, Rebollar-González V, Narváez-David R, Dorantes-García J.
    Rev Invest Clin; 2007 Sep 01; 59(2):103-7. PubMed ID: 17633796
    [Abstract] [Full Text] [Related]

  • 16. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F.
    Arch Cardiovasc Dis; 2014 Mar 01; 107(3):149-57. PubMed ID: 24630753
    [Abstract] [Full Text] [Related]

  • 17. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun 01; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 18. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.
    Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ.
    J Am Coll Cardiol; 2010 Jan 19; 55(3):243-50. PubMed ID: 20117403
    [Abstract] [Full Text] [Related]

  • 19. New treatment option for heart failure patients: eplerenone.
    Southworth MR, Cavallari LH.
    J Cardiovasc Nurs; 2004 Jan 19; 19(6):390-5. PubMed ID: 15529060
    [Abstract] [Full Text] [Related]

  • 20. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F.
    Circulation; 2009 May 12; 119(18):2471-9. PubMed ID: 19398668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.